MA43756A - Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine - Google Patents
Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholineInfo
- Publication number
- MA43756A MA43756A MA043756A MA43756A MA43756A MA 43756 A MA43756 A MA 43756A MA 043756 A MA043756 A MA 043756A MA 43756 A MA43756 A MA 43756A MA 43756 A MA43756 A MA 43756A
- Authority
- MA
- Morocco
- Prior art keywords
- acetylcholine receptor
- nicotinic acetylcholine
- allosteric modulators
- allosteric
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Control Of El Displays (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662311888P | 2016-03-22 | 2016-03-22 | |
US201662369778P | 2016-08-02 | 2016-08-02 | |
PCT/US2017/023127 WO2017165256A1 (fr) | 2016-03-22 | 2017-03-20 | Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine |
Publications (2)
Publication Number | Publication Date |
---|---|
MA43756A true MA43756A (fr) | 2021-05-19 |
MA43756B1 MA43756B1 (fr) | 2021-11-30 |
Family
ID=58455680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA43756A MA43756B1 (fr) | 2016-03-22 | 2017-03-20 | Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine |
Country Status (39)
Country | Link |
---|---|
US (3) | US20190337910A1 (fr) |
EP (2) | EP3978479A1 (fr) |
JP (1) | JP6526352B2 (fr) |
KR (1) | KR102203552B1 (fr) |
CN (1) | CN109153649B (fr) |
AR (1) | AR107928A1 (fr) |
AU (1) | AU2017237930B2 (fr) |
CA (1) | CA3018185C (fr) |
CL (1) | CL2018002697A1 (fr) |
CO (1) | CO2018009889A2 (fr) |
CR (1) | CR20180452A (fr) |
CY (1) | CY1124828T1 (fr) |
DK (1) | DK3433234T3 (fr) |
DO (1) | DOP2018000204A (fr) |
EC (1) | ECSP18078877A (fr) |
ES (1) | ES2901197T3 (fr) |
GE (1) | GEP20207149B (fr) |
HR (1) | HRP20211960T1 (fr) |
HU (1) | HUE057460T2 (fr) |
IL (1) | IL261807A (fr) |
JO (1) | JOP20170067B1 (fr) |
LT (1) | LT3433234T (fr) |
MA (1) | MA43756B1 (fr) |
MD (1) | MD3433234T2 (fr) |
MX (1) | MX2018011453A (fr) |
MY (1) | MY195948A (fr) |
PE (1) | PE20181851A1 (fr) |
PH (1) | PH12018502028A1 (fr) |
PL (1) | PL3433234T3 (fr) |
PT (1) | PT3433234T (fr) |
RS (1) | RS62704B1 (fr) |
SG (1) | SG11201808220VA (fr) |
SI (1) | SI3433234T1 (fr) |
SV (1) | SV2018005743A (fr) |
TN (1) | TN2018000322A1 (fr) |
TW (1) | TWI616438B (fr) |
UA (1) | UA120571C2 (fr) |
WO (1) | WO2017165256A1 (fr) |
ZA (1) | ZA201806141B (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3283459B1 (fr) | 2015-04-17 | 2019-05-22 | Dow Agrosciences LLC | Molécules présentant une utilité en tant que pesticides, ainsi qu'intermédiaires, compositions, et procédés associés |
WO2018071327A1 (fr) | 2016-10-12 | 2018-04-19 | Dow Agrosciences Llc | Molécules à usage pesticide et intermédiaires, compositions et procédés associés |
US10870630B2 (en) * | 2016-11-01 | 2020-12-22 | Merck Sharp & Dohme Corp. | Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors |
WO2018165520A1 (fr) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Composés inhibiteurs de métalloenzymes |
WO2019000238A1 (fr) * | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | Modulateurs allostériques de 5-(pyridin-3-yl)oxazole du récepteur muscarinique m4 de l'acétylcholine |
US11198687B2 (en) | 2017-09-19 | 2021-12-14 | Merck Sharp & Dohme Corp. | Heteroaryl allosteric modulators of nicotinic acetylcholine receptors |
GEP20227409B (en) * | 2018-05-01 | 2022-09-12 | Merck Sharp & Dohme | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors |
HU231478B1 (hu) | 2018-07-13 | 2024-02-28 | Richter Gedeon Nyrt. | Szubsztituált (aza)indol származékok |
HU231333B1 (hu) * | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
HU231414B1 (hu) | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
TW202408984A (zh) * | 2018-11-26 | 2024-03-01 | 美商富曼西公司 | 用於防治無脊椎害蟲的間二醯胺化合物 |
US20220119351A1 (en) * | 2019-05-02 | 2022-04-21 | Merck Sharp & Dohme Corp. | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors |
US20220396571A1 (en) * | 2019-11-05 | 2022-12-15 | Merck Sharp & Dohme Corp. | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors |
CN111233783B (zh) * | 2020-03-13 | 2021-11-16 | 温州大学 | 异噻唑-4-基二硫化物衍生物的合成方法 |
WO2023049058A1 (fr) * | 2021-09-21 | 2023-03-30 | Merck Sharp & Dohme Llc | Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine |
EP4415717A1 (fr) * | 2021-10-12 | 2024-08-21 | Brown University | Traitements de glioblastome multiforme |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3487154A (en) | 1967-04-03 | 1969-12-30 | Smithkline Corp | Method of lowering blood pressure |
US3522302A (en) | 1967-05-16 | 1970-07-28 | Smithkline Corp | P-(2-aminocycloalkyl)benzenesulfonamides |
FR2508033A1 (fr) | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | Aryl-1 aminomethyl-2 cyclopropanes carboxylates (z), leur preparation et leur application en tant que medicaments utiles dans le traitement d'algies diverses |
US5286736A (en) | 1990-11-22 | 1994-02-15 | Dr. Karl Thomae Gmbh | Pyridyl compounds and pharmaceutical compositions containing these compounds |
TW394761B (en) | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
FR2751645B1 (fr) | 1996-07-29 | 1998-12-24 | Sanofi Sa | Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales |
AR017014A1 (es) | 1997-07-22 | 2001-08-22 | Astrazeneca Ab | Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos |
IL137812A0 (en) | 1998-02-17 | 2001-10-31 | Astrazeneca Uk Ltd | Novel triazolo (4,5-d) pyrimidine compounds |
SE9802574D0 (sv) | 1998-07-17 | 1998-07-17 | Astra Pharma Prod | Novel compounds |
US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
WO2001055146A1 (fr) | 2000-01-29 | 2001-08-02 | Lg Chem Investment Ltd. | INHIBITEURS DU FACTEUR Xa CONTENANT DES ARYLAMIDINES ET DES DERIVES, ET PROMEDICAMENTS OBTENUS A PARTIR DESDITS INHIBITEURS |
US6630469B2 (en) | 2000-05-09 | 2003-10-07 | Bristol-Myers Squibb Company | 5-HT7 receptor antagonists |
FR2810664B1 (fr) * | 2000-06-27 | 2004-12-24 | Adir | Nouveaux composes cyclopropaniques 1,1 et 1,2-dissubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CA2442525A1 (fr) | 2001-03-29 | 2002-10-10 | Mendi Higgins | Derives de cyclopropylindole utilises en tant qu'inhibiteurs selectifs de recaptage de la serotonine |
WO2003082190A2 (fr) | 2002-03-26 | 2003-10-09 | Merck & Co., Inc. | Amides spirocycliques en tant que modulateurs du recepteur cannabinoide |
PT1585739E (pt) | 2003-01-06 | 2011-05-13 | Lilly Co Eli | Arilciclopropilacetamidas substitu?das como activadores da glucocinase |
EP1833804A1 (fr) * | 2004-12-28 | 2007-09-19 | AstraZeneca AB | Modulateurs de type arylsulfonamide |
JP2009506063A (ja) * | 2005-08-24 | 2009-02-12 | リブ−エックス ファーマシューティカルズ,インコーポレイテッド | トリアゾール化合物ならびにこれを作製する方法および使用する方法 |
US20080255069A1 (en) | 2005-09-09 | 2008-10-16 | R & R Inc. | Medicament for Preventive and/or Therapeutic Treatment of Bowel Disease |
AU2008307195B2 (en) | 2007-10-04 | 2012-11-22 | F. Hoffmann-La Roche Ag | Cyclopropyl aryl amide derivatives and uses thereof |
JP5437267B2 (ja) | 2007-12-19 | 2014-03-12 | アムジエン・インコーポレーテツド | 炎症モジュレーターとしてのフェニル酢酸誘導体 |
WO2009086303A2 (fr) | 2007-12-21 | 2009-07-09 | University Of Rochester | Procédé permettant de modifier la durée de vie d'organismes eucaryotes |
ATE556998T1 (de) | 2008-08-12 | 2012-05-15 | Hoffmann La Roche | Salicylamidderivate als nikotinische alpha-7- modulatoren |
JP2012512834A (ja) | 2008-12-19 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 炎症、喘息及びcopdの処置のためのccr2受容体アンタゴニストとしての環状ピリミジン−4−カルボキサミド |
WO2010084160A1 (fr) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Dérivés de phénylcyclopropylamine et leur utilisation médicale |
TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
PT2455376E (pt) | 2009-06-11 | 2015-03-04 | Abbvie Bahamas Ltd | Compostos heterocíclicos como inibidores do vírus da hepatite c (hcv) |
WO2010144959A1 (fr) | 2009-06-18 | 2010-12-23 | Fibrotech Therapeutics Pty Ltd | Analogues d'agents antifibrotiques |
EP2464228B1 (fr) * | 2009-08-13 | 2017-12-06 | Merck Sharp & Dohme Corp. | Composés cyclopropyle substitués, compositions contenant de tels composés et procédés de traitement |
US9303027B2 (en) | 2010-07-19 | 2016-04-05 | Dr. Reddy's Laboratories Ltd. | Kappa opioid receptor agonists |
WO2012047852A2 (fr) | 2010-10-07 | 2012-04-12 | The J. David Gladstone Institutes | Compositions et procédés de modulation de la transcription de virus d'immunodéficience |
EP2651885A1 (fr) | 2010-12-16 | 2013-10-23 | Abbvie Inc. | Composés antiviraux |
KR101925971B1 (ko) | 2011-01-28 | 2018-12-06 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
US9062013B2 (en) | 2011-02-02 | 2015-06-23 | Bionomics Limited | Positive allosteric modulators of the α7 nicotinic acetylcholine receptor and uses thereof |
SI2678327T1 (sl) | 2011-02-23 | 2017-01-31 | Lupin Limited Kalpataru Inspire | Derivati heteroarila kot alfa 7 nachr modulatorji |
WO2012151361A1 (fr) | 2011-05-03 | 2012-11-08 | Concert Pharmaceuticals Inc. | Dérivés de carbamoylpyridone |
WO2013005153A1 (fr) | 2011-07-05 | 2013-01-10 | Lupin Limited | Dérivés de biaryle en tant que modulateurs de nachr |
UA111746C2 (uk) * | 2011-07-08 | 2016-06-10 | Х. Луннбек А/С | Позитивні алостеричні модулятори нікотинового рецептора ацетилхоліну |
US8598213B2 (en) | 2011-07-08 | 2013-12-03 | H. Lundbeck A/S | Positive allosteric modulators of nicotinic acetylcholine receptor |
EP2742029B1 (fr) | 2011-08-08 | 2016-10-05 | Merck Patent GmbH | N-(benzimimdazol-2-yl)-cyclopropane carboxamides comme anatgonistes d'acide lysophosphatidique |
WO2014006117A1 (fr) | 2012-07-06 | 2014-01-09 | H. Lundbeck A/S | Nouveaux modulateurs allostériques positifs de récepteur nicotinique à l'acétylcholine |
WO2014019023A1 (fr) * | 2012-08-01 | 2014-02-06 | Bionomics Limited | Modulateurs du récepteur α7 nicotinique d'acétylcholine et leurs utilisations |
CN104837811A (zh) * | 2012-12-10 | 2015-08-12 | H.隆德贝克有限公司 | 烟碱乙酰胆碱受体的新的正向別构调节剂 |
MY174813A (en) | 2013-03-15 | 2020-05-16 | Zymeworks Inc | Cytotoxic and anti-mitotic compounds, and methods of using the same |
WO2014172759A1 (fr) | 2013-04-24 | 2014-10-30 | Bionomics Limited | MODULATEURS DU RÉCEPTEUR NICOTINIQUE α7 DE L'ACÉTYLCHOLINE ET UTILISATIONS DE CEUX-CI - III |
TW201446243A (zh) | 2013-06-03 | 2014-12-16 | Lupin Ltd | 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑 |
CN106255513B (zh) | 2013-12-27 | 2022-01-14 | 酵活有限公司 | 用于药物偶联物的含磺酰胺连接*** |
JP6615115B2 (ja) | 2013-12-27 | 2019-12-04 | ザイムワークス インコーポレイティド | Var2csa−薬物コンジュゲート |
EP3151833A4 (fr) | 2014-06-04 | 2018-01-10 | Thomas Helledays Stiftelse För Medicinsk Forskning | Inhibiteurs de mth1 destinés au traitement des états inflammatoires et auto-immuns |
EP3152195A4 (fr) | 2014-06-04 | 2017-12-13 | Thomas Helledays Stiftelse För Medicinsk Forskning | Inhibiteurs mth1 pour le traitement du cancer |
WO2015191799A1 (fr) * | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Modulateurs de la sous-unité alpha-7 du récepteur nicotinique de l'acétylcholine et leurs utilisations |
-
2017
- 2017-03-20 MY MYPI2018001607A patent/MY195948A/en unknown
- 2017-03-20 JO JOP/2017/0067A patent/JOP20170067B1/ar active
- 2017-03-20 LT LTEPPCT/US2017/023127T patent/LT3433234T/lt unknown
- 2017-03-20 HR HRP20211960TT patent/HRP20211960T1/hr unknown
- 2017-03-20 HU HUE17714623A patent/HUE057460T2/hu unknown
- 2017-03-20 GE GEAP201714908A patent/GEP20207149B/en unknown
- 2017-03-20 WO PCT/US2017/023127 patent/WO2017165256A1/fr active Application Filing
- 2017-03-20 JP JP2018549170A patent/JP6526352B2/ja active Active
- 2017-03-20 CA CA3018185A patent/CA3018185C/fr active Active
- 2017-03-20 UA UAA201809635A patent/UA120571C2/uk unknown
- 2017-03-20 PE PE2018001841A patent/PE20181851A1/es unknown
- 2017-03-20 EP EP21204099.2A patent/EP3978479A1/fr not_active Withdrawn
- 2017-03-20 CN CN201780031228.9A patent/CN109153649B/zh active Active
- 2017-03-20 US US16/087,382 patent/US20190337910A1/en not_active Abandoned
- 2017-03-20 MD MDE20190130T patent/MD3433234T2/ro unknown
- 2017-03-20 CR CR20180452A patent/CR20180452A/es unknown
- 2017-03-20 PL PL17714623T patent/PL3433234T3/pl unknown
- 2017-03-20 MX MX2018011453A patent/MX2018011453A/es active IP Right Grant
- 2017-03-20 KR KR1020187029892A patent/KR102203552B1/ko active IP Right Grant
- 2017-03-20 RS RS20211533A patent/RS62704B1/sr unknown
- 2017-03-20 US US15/463,336 patent/US9840481B2/en active Active
- 2017-03-20 SI SI201730988T patent/SI3433234T1/sl unknown
- 2017-03-20 ES ES17714623T patent/ES2901197T3/es active Active
- 2017-03-20 AR ARP170100686A patent/AR107928A1/es unknown
- 2017-03-20 TW TW106109075A patent/TWI616438B/zh active
- 2017-03-20 SG SG11201808220VA patent/SG11201808220VA/en unknown
- 2017-03-20 EP EP17714623.0A patent/EP3433234B1/fr active Active
- 2017-03-20 DK DK17714623.0T patent/DK3433234T3/da active
- 2017-03-20 PT PT177146230T patent/PT3433234T/pt unknown
- 2017-03-20 AU AU2017237930A patent/AU2017237930B2/en active Active
- 2017-03-20 TN TNP/2018/000322A patent/TN2018000322A1/en unknown
- 2017-03-20 MA MA43756A patent/MA43756B1/fr unknown
- 2017-10-09 US US15/727,982 patent/US9926285B2/en active Active
-
2018
- 2018-09-13 ZA ZA2018/06141A patent/ZA201806141B/en unknown
- 2018-09-16 IL IL261807A patent/IL261807A/en active IP Right Grant
- 2018-09-19 CO CONC2018/0009889A patent/CO2018009889A2/es unknown
- 2018-09-19 SV SV2018005743A patent/SV2018005743A/es unknown
- 2018-09-21 DO DO2018000204A patent/DOP2018000204A/es unknown
- 2018-09-21 PH PH12018502028A patent/PH12018502028A1/en unknown
- 2018-09-21 CL CL2018002697A patent/CL2018002697A1/es unknown
- 2018-10-19 EC ECSENADI201878877A patent/ECSP18078877A/es unknown
-
2021
- 2021-12-16 CY CY20211101106T patent/CY1124828T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43756A (fr) | Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine | |
MA45463A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
MA43382A (fr) | Modulateurs des récepteurs des chimiokines | |
MA46952A (fr) | Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet | |
MA42924A (fr) | Variants optimisés d'anticorps anti-vegf | |
MA44253A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1 | |
DK3359160T3 (da) | Farnesoid x receptor modulatorer | |
DK3490986T3 (da) | Piperidin-cxcr7-receptormodulatorer | |
DK3193880T3 (da) | Hæmning af den transiente receptor-potential-A1-ionkanal | |
IL272017A (en) | Positive allosteric modulators of muscarinic m2 receptor | |
MA51337A (fr) | Inhibiteurs spiro exo-aza de l'interaction ménine-mll | |
FR3056393B1 (fr) | Orthese d'extension de machoires | |
MA52482A (fr) | Modulateurs allostériques de spiropipéridine des récepteurs nicotiniques de l'acétylcholine | |
FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
IL266505A (en) | Heterocyclic modulators of lipid synthesis | |
MA52555A (fr) | Modulateurs du récepteur des oestrogènes | |
MA47127A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
MA46722A (fr) | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 | |
MA47126A (fr) | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 | |
MA46899A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
MA49564A (fr) | Modulateurs thérapeutiques du mode inverse de l'atp synthase | |
MA50435A (fr) | Anticorps anti-ligand anti-cd40 thérapeutiques | |
MA51036A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
FR3056399B1 (fr) | Composition cosmetique fixatrice de maquillage | |
ES2747993T8 (es) | Composiciones farmacéuticas de liberación prolongada de levetiracetam |